|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Inclusion criteria were histologic diagnosis of benign nodule (control) and stage I or II adenocarcinoma harboring either p.L858R or ex</span>on19 delEGFR mutations.
|
30309763 |
2018 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Expert consensus guidelines have defined minimum requirements for routine testing and identification of classical epidermal growth factor (EGFR) mutations (ie, exon 19 deletions and exon 21 L858R substitution) and anaplastic lymphoma kinase (ALK) rearrangements in advanced non-small-cell lung cancers of adenocarcinoma histology, with the intent of permitting use of these predictive biomarkers to select patients who will derive maximal benefit from approved oral tyrosine kinase inhibitors (TKIs) directed against EGFR and ALK, respectively.
|
27381270 |
2016 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Analyses of the EGFR mutation in separately microdissected specimens from adenocarcinoma and spindle cell components revealed that both components possessed the L858R point mutation.
|
21556797 |
2011 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This case represents the first evidence that 1) bevacizumab combined with osimertinib can significantly relieve tumor growth and respiratory symptoms in non-small-cell lung cancer patients with osimertinib resistance and 2) the clinical use of osimertinib, bevacizumab, and brigatinib is effective as combination therapy for pulmonary adenocarcinoma in the presence of triple EGFR mutations of L858R, T790M, and <i>cis</i>-C797S.
|
30233215 |
2018 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Finally, we showed that EGFR(L858R)/Rhob(+/+) mice developed mainly diffuse lung tumors with a lepidic pattern, whereas EGFR(L858R)/Rhob(+/-) and EGFR(L858R)/Rhob(-/-) developed a greater number of tumors, and aggressive adenocarcinomas with invasive properties.
|
25320360 |
2014 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We enrolled consecutive patients with operable adenocarcinoma which harbored 19del or L858R to investigate the clinicopathologic characteristics and prognostic outcomes.
|
29026990 |
2018 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Plasma DNA samples from 73 patients with stage IIIB to IV adenocarcinoma were analyzed for EGFR mutations in exons 19 (deletion mutation) and 21 (L858R mutation) using direct DNA sequencing, DHPLC and Scorpions ARMS.
|
21518597 |
2011 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Eighteen out of 20 large cell carcinomas, not otherwise specified, had glandular differentiation upon immunohistochemistry, with an exon 21 L858R EGFR mutation in one (5 %) tumor, an exon 2 KRAS mutation in eight (40 %) tumors, and an ALK translocation in one (5 %) tumor, whereas two tumors positive for CK7 and CK5/6 and negative for all other markers were considered adenocarcinoma.
|
24221342 |
2014 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 69-year-old Caucasian female former light-smoker presented with stage IV EGFR L858R positive adenocarcinoma who developed EGFR T790M mutation after 8 month treatment of erlotinib.
|
28625641 |
2017 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The patient was a 67-year-old male with a diagnosis of metastatic pulmonary adenocarcinoma with an L858R mutation on exon 21.
|
31371992 |
2019 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In the ADC/BAC group, KRAS mutations were more frequent in man (P<0.02) and EGFR mutations (exon 19 deletion and L858R) demonstrated a tendency towards worse disease-free survival (P=0.056).
|
23357969 |
2014 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Herein, we report a case of 2 synchronous lung adenocarcinomas composed of 2 distinct pathological subtypes with different EGFR mutations: homozygous deletion in exon 19 in the papillary subtype of adenocarcinoma and a point mutation of L858R in exon 21 in the tubular adenocarcinoma.
|
18186961 |
2007 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Pulmonary adenocarcinoma tissue from 20 previously genotyped specimens was prepared for immunohistochemical staining by two antibodies that recognise products of in-frame deletions in exon 19 (E746_A750del) and a point mutation that replaces leucine with arginine at codon 858 in exon 21 (L858R) of the EGFR gene.
|
21187519 |
2010 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We report here a case of pulmonary adenocarcinoma with concomitant EGFR mutation in exon 21 (L858R) and ALK rearrangement in naive and relapsed tumors.
|
25312989 |
2014 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Advanced unresectable pulmonary adenocarcinoma with the epidermal growth factor receptor (EGFR) exon 21 L858R point mutation (Ex21) is associated with a poor prognosis.
|
27553497 |
2016 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We describe here on a hitherto unreported mechanism of EGFR TKI resistance synchronously combining squamous-cell carcinoma change and occurrence of the EGFR exon 20 S768I secondary mutation in a 43 year-old woman with stage IV adenocarcinoma harbouring EGFR exon 21 L858R mutation.
|
28024692 |
2017 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In multivariate analysis, adenocarcinoma (hazard ratio, HR, 12.25; 95% CI, 37.7-41.10; p < 0.001) and major mutations (deletions in exon 19 and L858R point mutation in exon 21; HR, 2.46; 95% CI, 1.14-5.28; p = 0.022) were significant predictors of longer PFS.
|
24457318 |
2014 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The L858R mutation was significantly correlated with gender (women versus men, P < 0.0001), Brinkman index (600 < or = versus 600, P = 0.001), pathologic subtypes (adenocarcinoma versus nonadenocarcinoma, P = 0.007), and differentiation status of the lung cancers (well versus moderately or poorly, P = 0.0439), whereas the deletion mutants were not.
|
15837743 |
2005 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In particular, 3 of 4 adenocarcinomas with EGFR mutations (all L858R point mutations in women, never or former smokers) had a concomitant and identical mutation in AAH, and 2 of 4 adenocarcinomas with K-ras mutations (both at codon 12 in women, a never and a current smoker) showed the same mutation in concomitant AAH.All cases were wild-type for HER2.
|
18208799 |
2008 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Seven adenocarcinoma components were EGFR mutated: five exon 19 deletions and two mutations in exon 21 (L833_V834delinsFL and L858R).Four SCLC components were EGFR mutated.
|
24457237 |
2013 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Two weeks after induction with doxycycline, mice that express the EGFR(L858R) allele show diffuse lung cancer highly reminiscent of human bronchioloalveolar carcinoma and later develop interspersed multifocal adenocarcinomas.
|
16705038 |
2006 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Pretreatment evaluation of EGFR mutations in the resected primary adenocarcinoma specimen showed an L858R mutation in exon 21.
|
24852875 |
2014 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We analyzed three major EGFR mutations (L858R in exon 21, E746_A750del in exon 19 and T790M in exon 20) in 80 fresh liquid cytology specimens of adenocarcinoma (ADC) or NSCLC-not otherwise specified (NOS) via the EGFR d-PCR assay and conventional real-time PCR assay using the therascreen® EGFR RGQ PCR kit (Therascreen assay).
|
27922678 |
2017 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR mutations (ex19del and L858R) were detected in 1759/8716 (20.2 %) adenocarcinomas, 28/669 (4.2 %) squamous cell carcinomas (SCC) and 8/119 (6.7 %) large cell carcinomas.
|
27259329 |
2016 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 62-year-old Asian male never smoker who presented with stage IV EGFR L858R-positive adenocarcinoma developed EGFR T790 M mutation after 14 months of treatment with erlotinib combined with thoracic radiotherapy as first-line therapy.
|
30400855 |
2018 |